FDA launches Rare Disease Framework Initiative to align evidence expectations for rare disease therapies

The US Food and Drug Administration (FDA) has announced its Rare Disease Framework Initiative, outlining plans to reassess evidence requirements for rare disease therapies. The initiative aims to establish a more consistent, fit-for-purpose approach to drug development and regulatory review that accounts for disease characteristics, patient needs, and the challenges of generating clinical evidence in small populations.

The Baseline

• The FDA has launched its Rare Disease Framework Initiative to establish more consistent, fit-for-purpose evidence requirements for rare disease therapies.
• The initiative will consider patient needs, disease characteristics, and flexible evidence-generation approaches, including real-world evidence and innovative trial designs.
• Stakeholder engagement will inform potential updates to regulatory guidance, policies, and review practices across FDA divisions.

The FDA is undertaking a review of how it applies evidence requirements to rare disease therapies, seeking to improve consistency across review divisions while accounting for the challenges of developing treatments for small, heterogeneous patient populations. Through its Rare Disease Framework Initiative, the agency will examine existing policies and practices and seek stakeholder input on where changes could better support development while maintaining standards for safety and effectiveness.

According to the agency, approximately 30 million Americans live with a rare disease, yet only around 5% of recognized rare diseases have an FDA-approved treatment. Despite introducing regulatory flexibility and targeted programs to support rare disease drug development, small patient populations, disease heterogeneity and limited natural history data continue to present challenges for evidence generation and regulatory assessment.

An accompanying white paper, published on October 14, 2026, sets out the agency’s ambition to make flexibility in evidence requirements a more consistent feature of rare disease development and review. As the white paper explains:

“The goal is a regulatory framework where fit-for-purpose evidentiary expectations are the norm for all rare disease applications; the FDA will work closely with sponsors and patients to support innovative approaches to generating evidence that will meet the FDA’s rigorous statutory standard of safety and effectiveness.”

Under the proposed approach, regulatory advice and evidence expectations would reflect what can reasonably be generated for each therapy, taking account of disease onset and progression, target populations, patient needs, and product characteristics. The FDA intends to communicate these expectations throughout development and review while maintaining statutory standards for safety and effectiveness.

Amy Comstock Rick, Director of the FDA’s Rare Disease Innovation Hub, commented:

“A bold vision to reimagine the framework for rare disease drug development that builds on key learnings and milestones is necessary to meet this moment. This new framework will enhance consistency and predictability for both sponsors and for patients.”

The initiative will review existing policies, programs, guidance, and regulations, covering development from pre-investigational new drug (pre-IND) engagement through post-approval obligations. It aims to build on existing FDA programs while promoting greater consistency across the Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER).

The initiative prioritizes incorporating patient perspectives early in development and at defined regulatory milestones, including views on disease burden, benefit-risk priorities, and meaningful measures of treatment progress. The FDA also proposes greater involvement of external experts, particularly where patient populations are small and natural history data are limited.

The white paper identifies genomic characterization, platform trial designs, real-world evidence (RWE) methodologies, and Bayesian statistical approaches as developments that could inform evidence generation and regulatory assessment in small populations.

Led by the FDA’s Rare Disease Innovation Hub, the initiative will gather stakeholder input through a hybrid public meeting on October 28, 2026, facilitated by the Reagan-Udall Foundation for the FDA, followed by Requests for Information, sector-specific roundtables, and internal FDA consultations. The findings could inform revisions to regulations and guidance on trial design, endpoints and statistical methods, alongside greater alignment across review divisions and additional staff training. The FDA has not specified a timeline for completing the framework.